Keywords: AstraZeneca, Bristol-Myers Squibb, Forxiga, Type 2 diabets, SMC, Scotland

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes

Article | 14 January 2013

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA says that the Scottish Medicines ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in